Design and development of polymer conjugates as anti-angiogenic agents

Advanced Drug Delivery Reviews

Volumn 61, Issue 13, 2009, Pages 1159-1176

  Segal, Ehud ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANGIOGENESIS INHIBITORS; ANTI-ANGIOGENIC THERAPY; ANTI-CANCER AGENTS; CANCER THERAPY; CANCER TREATMENT; CLEARANCE RATES; DESIGN AND DEVELOPMENT; INNOVATIVE APPROACHES; LOW MOLECULAR WEIGHT; LOW-MOLECULAR-WEIGHT COMPOUNDS; NEW MODALITY; PHARMACOKINETIC PROFILES; POLYMER CONJUGATE; POLYMER THERAPEUTICS; POLYMERIC CARRIERS; THERAPEUTIC POTENTIALS; TUMOR ANGIOGENESIS; TUMOR PROGRESSIONS; VASCULATURE;

AMINES; BLOOD VESSELS; CHEMOTHERAPY; LIGANDS; POLYMERS; PROTEINS; TUMORS;

FUNCTIONAL POLYMERS;

ALENDRONATE FUMAGILLOL CHLOROACETYLCARBAMATE N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; ALENDRONATE PACLITAXEL N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA POLY(MALIC ACID); CAPLOSTATIN; DISTEAROYLPHOSPHATIDYLETHANOLAMINE ALANYLPROPYLARGINYLPROPYLGLYCINE POLYETHYLENE GLYCOL; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FUMAGILLOL CHLOROACETYLCARBAMATE; FUMAGILLOL CHLOROACETYLCARBAMATE POLYVINYL ALCOHOL; LIPOSOME; LODAMIN; MACROGOL; MALIC ACID DERIVATIVE; MICROSPHERE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PACLITAXEL; POLYCEFIN; POLYETHYLENEIMINE; POLYGLACTIN; POLYGLUTAMIC ACID; POLYLACTIC ACID; POLYMER; POLYVINYL ALCOHOL; QUINIC ACID N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; RGD4C N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; RGDFK N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; COLON CARCINOMA; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GENE DELIVERY SYSTEM; GLIOBLASTOMA; LUNG CARCINOMA; MELANOMA; NANOMEDICINE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SUBRETINAL NEOVASCULARIZATION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYMERS;

EID: 70349981387     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.06.005     Document Type: Review

References (169)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
2. Carmeliet P., and Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann. N. Y. Acad. Sci. 902 (2000) 249-262 discussion 262-244
3. Haag R., and Kratz F. Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. Engl. 45 (2006) 1198-1215
4. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci., Polym. Symp. 51 (1975) 135-153
5. Godwin A., Bolina K., Clochard M., Dinand E., Rankin S., Simic S., and Brocchini S. New strategies for polymer development in pharmaceutical science-a short review. J. Pharm. Pharmacol. 53 (2001) 1175-1184
6. Rihova B. Immunomodulating activities of soluble synthetic polymer-bound drugs. Adv. Drug Deliv. Rev. 54 (2002) 653-674
7. Duncan R., Ringsdorf H., and Satchi-Fainaro R. Polymer therapeutics-polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. J. Drug Target. 14 (2006) 337-341
8. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986) 6387-6392
9. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
10. Holmgren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1 (1995) 149-153
11. Pezzella F., Pastorino U., Tagliabue E., Andreola S., Sozzi G., Gasparini G., Menard S., Gatter K.C., Harris A.L., Fox S., Buyse M., Pilotti S., Pierotti M., and Rilke F. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 151 (1997) 1417-1423
12. Folkman J. Successful treatment of an angiogenic disease. N. Engl. J. Med. 320 (1989) 1211-1212
13. Naumov G.N., Akslen L.A., and Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 5 (2006) 1779-1787
14. Hagedorn M., and Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit. Rev. Oncol. Hematol. 34 (2000) 89-110
15. Folkman J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3 (2003) 643-651
16. Folkman J. Endogenous inhibitors of angiogenesis. Harvey Lect. 92 (1996) 65-82
17. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol. Ther. 2 (2003) S127-133
18. Folkman J., Browder T., and Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb. Haemost. 86 (2001) 23-33
19. Goh P.P., Sze D.M., and Roufogalis B.D. Molecular and cellular regulators of cancer angiogenesis. Curr. Cancer Drug Targets 7 (2007) 743-758
20. Hida K., Hida Y., Amin D.N., Flint A.F., Panigrahy D., Morton C.C., and Klagsbrun M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 64 (2004) 8249-8255
21. Hlatky L., Hahnfeldt P., and Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94 (2002) 883-893
22. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000) 1878-1886
23. Dutour A., and Rigaud M. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies. Anticancer Res. 25 (2005) 3799-3807
24. Alessi P., Ebbinghaus C., and Neri D. Molecular targeting of angiogenesis. Biochim. Biophys. Acta 1654 (2004) 39-49
25. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 423-436
26. Kieran M.W., Turner C.D., Rubin J.B., Chi S.N., Zimmerman M.A., Chordas C., Klement G., Laforme A., Gordon A., Thomas A., Neuberg D., Browder T., and Folkman J. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J. Pediatr. Hematol. Oncol. 27 (2005) 573-581
27. Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol. 2 (2001) 733-740
28. Gately S., and Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7 (2001) 427-436
29. Eichhorn M.E., Strieth S., and Dellian M. Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist. Updat. 7 (2004) 125-138
30. Zangari M., Anaissie E., Stopeck A., Morimoto A., Tan N., Lancet J., Cooper M., Hannah A., Garcia-Manero G., Faderl S., Kantarjian H., Cherrington J., Albitar M., and Giles F.J. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin. Cancer Res. 10 (2004) 88-95
31. Mauriz J.L., and Gonzalez-Gallego J. Antiangiogenic drugs: current knowledge and new approaches to cancer therapy. J. Pharm. Sci. 97 (2008) 4129-4154
32. Quesada A.R., Munoz-Chapuli R., and Medina M.A. Anti-angiogenic drugs: from bench to clinical trials. Med. Res. Rev. 26 (2006) 483-530
33. Ong V.S., Stamm G.E., Menacherry S., and Chu S. Quantitation of TNP-470 and its metabolites in human plasma: sample handling, assay performance and stability. J. Chromatogr., B, Biomed. Sci. Appl. 710 (1998) 173-182
34. Eriksson T., Bjorkman S., Roth B., and Hoglund P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J. Pharm. Pharmacol. 52 (2000) 807-817
35. Bergman E., Forsell P., Persson E.M., Knutson L., Dickinson P., Smith R., Swaisland H., Farmer M.R., Cantarini M.V., and Lennernas H. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int. J. Pharm. 341 (2007) 134-142
36. Langer R. Drug delivery and targeting. Nature 392 (1998) 5-10
37. Rihova B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 29 (1998) 273-289
38. Jain R.K. Transport, of molecules in the tumor interstitium: a review. Cancer Res. 47 (1987) 3039-3051
39. Maeda H., and Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carr. Syst. 6 (1989) 193-210
40. Maeda H., Sawa T., and Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74 (2001) 47-61
41. Caliceti P., and Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55 (2003) 1261-1277
42. Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem. Soc. Trans. 35 (2007) 56-60
43. Iyer A.K., Khaled G., Fang J., and Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 (2006) 812-818
44. Maeda H., Akaike T., Wu J., Noguchi Y., and Sakata Y. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 33 (1996) 222-230
45. Maeda H., Fang J., Inutsuka T., and Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3 (2003) 319-328
46. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41 (2001) 189-207
47. Kopecek J., Kopeckova P., Minko T., and Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50 (2000) 61-81
48. Kuniyasu H., Yasui W., Pettaway C.A., Yano S., Oue N., Tahara E., and Fidler I.J. Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. Prostate 49 (2001) 19-29
49. Bottaro D.P., and Liotta L.A. Cancer: out of air is not out of action. Nature 423 (2003) 593-595
50. Jain R.K. Normalization, of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
51. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
52. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
53. Chappelow A.V., and Kaiser P.K. Neovascular age-related macular degeneration: potential therapies. Drugs 68 (2008) 1029-1036
54. Laird A.D., Christensen J.G., Li G., Carver J., Smith K., Xin X., Moss K.G., Louie S.G., Mendel D.B., and Cherrington J.M. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 16 (2002) 681-690
55. Beecken W.D., Engl T., Blaheta R., Bentas W., Achilles E.G., Jonas D., Shing Y., and Camphausen K. Angiogenesis inhibition by angiostatin, endostatin and TNP-470 prevents cyclophosphamide induced cystitis. Angiogenesis 7 (2004) 69-73
56. Satchi-Fainaro R., Mamluk R., Wang L., Short S.M., Nagy J.A., Feng D., Dvorak A.M., Dvorak H.F., Puder M., Mukhopadhyay D., and Folkman J. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7 (2005) 251-261
57. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer 2 (2002) 83-90
58. Folkman J. Angiogenic zip code. Nat. Biotechnol. 17 (1999) 749
59. Joyce J.A., Laakkonen P., Bernasconi M., Bergers G., Ruoslahti E., and Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4 (2003) 393-403
60. Scott J.K., and Smith G.P. Searching for peptide ligands with an epitope library. Science 249 (1990) 386-390
61. Pasqualini R., and Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 380 (1996) 364-366
62. Rajotte D., Arap W., Hagedorn M., Koivunen E., Pasqualini R., and Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102 (1998) 430-437
63. Pierschbacher M.D., and Ruoslahti E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 5985-5988
64. Arap W., Pasqualini R., and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998) 377-380
65. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., Bredesen D.E., and Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5 (1999) 1032-1038
66. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., and Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60 (2000) 722-727
67. Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., and Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 163 (2003) 871-878
68. Porkka K., Laakkonen P., Hoffman J.A., Bernasconi M., and Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7444-7449
69. Ozerdem U., Grako K.A., Dahlin-Huppe K., Monosov E., and Stallcup W.B. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 222 (2001) 218-227
70. Oku N., Asai T., Watanabe K., Kuromi K., Nagatsuka M., Kurohane K., Kikkawa H., Ogino K., Tanaka M., Ishikawa D., Tsukada H., Momose M., Nakayama J., and Taki T. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 21 (2002) 2662-2669
71. Arap W., Haedicke W., Bernasconi M., Kain R., Rajotte D., Krajewski S., Ellerby H.M., Bredesen D.E., Pasqualini R., and Ruoslahti E. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1527-1531
72. Schliemann C., and Neri D. Antibody-based targeting of the tumor vasculature. Biochim. Biophys. Acta 1776 (2007) 175-192
73. Deosarkar S.P., Malgor R., Fu J., Kohn L.D., Hanes J., and Goetz D.J. Polymeric particles conjugated with a ligand to VCAM-1 exhibit selective, avid, and focal adhesion to sites of atherosclerosis. Biotechnol. Bioeng. 101 (2008) 400-407
74. Sakhalkar H.S., Hanes J., Fu J., Benavides U., Malgor R., Borruso C.L., Kohn L.D., Kurjiaka D.T., and Goetz D.J. Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J. 19 (2005) 792-794
75. Muro S., Dziubla T., Qiu W., Leferovich J., Cui X., Berk E., and Muzykantov V.R. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J. Pharmacol. Exp. Ther. 317 (2006) 1161-1169
76. Muro S., Schuchman E.H., and Muzykantov V.R. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Molec. Ther. 13 (2006) 135-141
77. Sakhalkar H.S., Dalal M.K., Salem A.K., Ansari R., Fu J., Kiani M.F., Kurjiaka D.T., Hanes J., Shakesheff K.M., and Goetz D.J. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15895-15900
78. Rihova B., Ulbrich K., Kopecek J., and Mancal P. Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers-potential hapten or drug carriers. Folia Microbiol. (Praha) 28 (1983) 217-227
79. Duncan R., Cable H.C., Rejmanova P., Kopecek J., and Lloyd J.B. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim. Biophys. Acta 799 (1984) 1-8
80. Jensen K.D., Kopeckova P., Bridge J.H., and Kopecek J. The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells. AAPS PharmSci 3 (2001) E32
81. Chytil P., Etrych T., Konak C., Sirova M., Mrkvan T., Rihova B., and Ulbrich K. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification. J. Control. Release 115 (2006) 26-36
82. Kovar M., Strohalm J., Etrych T., Ulbrich K., and Rihova B. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug. Chem. 13 (2002) 206-215
83. Rihova B., Bilej M., Vetvicka V., Ulbrich K., Strohalm J., Kopecek J., and Duncan R. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10 (1989) 335-342
84. Satchi-Fainaro R., Wrasidlo W., Lode H.N., and Shabat D. Synthesis and characterization of a catalytic antibody-HPMA copolymer-Conjugate as a tool for tumor selective prodrug activation. Bioorg. Med. Chem. 10 (2002) 3023-3029
85. Satchi-Fainaro R., Hailu H., Davies J.W., Summerford C., and Duncan R. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug. Chem. 14 (2003) 797-804
86. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H., Schot M., Mandjes I.A., Zurlo M.G., Rocchetti M., Rosing H., Koopman F.J., and Beijnen J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12 (2001) 315-323
87. Gianasi E., Wasil M., Evagorou E.G., Keddle A., Wilson G., and Duncan R. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer 35 (1999) 994-1002
88. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., Corfas G., and Folkman J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10 (2004) 255-261
89. Nori A., Jensen K.D., Tijerina M., Kopeckova P., and Kopecek J. Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells. J. Control. Release 91 (2003) 53-59
90. Richardson S.C., Wallom K.L., Ferguson E.L., Deacon S.P., Davies M.W., Powell A.J., Piper R.C., and Duncan R. The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery. J. Control. Release 127 (2008) 1-11
91. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y.N., Satchi R., and Searle F. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release 74 (2001) 135-146
92. Kovar M., Kovar L., Subr V., Etrych T., Ulbrich K., Mrkvan T., Loucka J., and Rihova B. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro. J. Control. Release 99 (2004) 301-314
93. Pan H., Kopeckova P., Wang D., Yang J., Miller S., and Kopecek J. Water-soluble HPMA copolymer-prostaglandin E1 conjugates containing a cathepsin K sensitive spacer. J. Drug Target. 14 (2006) 425-435
94. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., and Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5 (1999) 83-94
95. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., and Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20 (2002) 1668-1676
96. Seymour L.W., Duncan R., Strohalm J., and Kopecek J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 21 (1987) 1341-1358
97. Dvorak M., Kopeckova P., and Kopecek J. High-molecular weight HPMA copolymer-adriamycin conjugates. J. Control. Release 60 (1999) 321-332
98. Pan H., Sima M., Kopeckova P., Wu K., Gao S., Liu J., Wang D., Miller S.C., and Kopecek J. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol. Pharmcol. 5 (2008) 548-558
99. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., and Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348 (1990) 555-557
100. Kudelka A.P., Levy T., Verschraegen C.F., Edwards C.L., Piamsomboon S., Termrungruanglert W., Freedman R.S., Kaplan A.L., Kieback D.G., Meyers C.A., Jaeckle K.A., Loyer E., Steger M., Mante R., Mavligit G., Killian A., Tang R.A., Gutterman J.U., and Kavanagh J.J. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. 3 (1997) 1501-1505
101. Kudelka A.P., Verschraegen C.F., and Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N. Engl. J. Med. 338 (1998) 991-992
102. Bhargava P., Marshall J.L., Rizvi N., Dahut W., Yoe J., Figuera M., Phipps K., Ong V.S., Kato A., and Hawkins M.J. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5 (1999) 1989-1995
103. Dezube B.J., Von Roenn J.H., Holden-Wiltse J., Cheung T.W., Remick S.C., Cooley T.P., Moore J., Sommadossi J.P., Shriver S.L., Suckow C.W., and Gill P.S. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J. Clin. Oncol. 16 (1998) 1444-1449
104. Mendichi R., Rizzo V., Gigli M., and Schieroni A.G. Fractionation and characterization of a conjugate between a polymeric drug-carrier and the antitumor drug camptothecin. Bioconjug. Chem. 13 (2002) 1253-1258
105. Satchi-Fainaro R. Targeting tumor vasculature: reality or a dream?. J. Drug Target. 10 (2002) 529-533
106. Chesler L., Goldenberg D.D., Seales I.T., Satchi-Fainaro R., Grimmer M., Collins R., Struett C., Nguyen K.N., Kim G., Tihan T., Bao Y., Brekken R.A., Bergers G., Folkman J., and Weiss W.A. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res. 67 (2007) 9435-9442
107. Folkman J. Angiogenesis. Annu. Rev. Med. 57 (2006) 1-18
108. Segal E., Pan H., Ofek P., Udagawa T., Kopečková P., Kopeček J., and Satchi-Fainaro R. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 4 4 (2009) e5233
109. Miller K., Erez R., Segal E., Shabat D., and Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. Engl. 48 (2009) 2949-2954
110. Y. Shamay, D. Paulin, G. Ashkenasy, and A. David, Multivalent display of quinic acid based ligands for targeting e-selectin expressing cells. J. Med. Chem. (in press).
111. Meyer A., Auernheimer J., Modlinger A., and Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12 (2006) 2723-2747
112. Ruoslahti E., and Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18 (2000) 813-827
113. Pasqualini R., Koivunen E., and Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15 (1997) 542-546
114. K-W. W., Vicent M.J., and Duncan R. Targeting endothelial cells using HPMA copolymer-doxorubicin-RGD conjugates. Proc. Int. Symp. Control. Release Bioact. Mater. 30 (2003) 491-492
115. Wan K.-W., Vicent M.J., and Duncan R. Targeting endothelial cells using HPMA copolymer-doxorubicin-RGD conjugates. Proc. Int. Symp. Control. Release Bioact. Mater. 30 (2003) 491-492
116. Pasqualini R., Arap W., and McDonald D.M. Probing the structural and molecular diversity of tumor vasculature. Trends Mol. Med. 8 (2002) 563-571
117. Mitra A., Mulholland J., Nan A., McNeill E., Ghandehari H., and Line B.R. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J. Control. Release 102 (2005) 191-201
118. Mitra A., Coleman T., Borgman M., Nan A., Ghandehari H., and Line B.R. Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. J. Control. Release 114 (2006) 175-183
119. Borgman M.P., Coleman T., Kolhatkar R.B., Geyser-Stoops S., Line B.R., and Ghandehari H. Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation. J. Control. Release 132 3 (2008) 193-199
120. A. Eldar, K. Miller, M. Vicent, and R. Satchi-Fainaro, Targeting αvβ3 Integrin on tumor vasculature using a novel polyglutamic acid-paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2]. (submitted for publication).
121. Gottler T., and Holler E. Screening for beta-poly(L-malate) binding proteins by affinity chromatography. Biochem. Biophys. Res. Commun. 341 (2006) 1119-1127
122. Hallmann R., Horn N., Selg M., Wendler O., Pausch F., and Sorokin L.M. Expression and function of laminins in the embryonic and mature vasculature. Physiol. Rev. 85 (2005) 979-1000
123. Ljubimova J.Y., Lakhter A.J., Loksh A., Yong W.H., Riedinger M.S., Miner J.H., Sorokin L.M., Ljubimov A.V., and Black K.L. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res. 61 (2001) 5601-5610
124. Fujiwara H., Gu J., and Sekiguchi K. Rac regulates integrin-mediated endothelial cell adhesion and migration on laminin-8. Exp. Cell Res. 292 (2004) 67-77
125. DeHahn K.C., Gonzales M., Gonzalez A.M., Hopkinson S.B., Chandel N.S., Brunelle J.K., and Jones J.C. The alpha4 laminin subunit regulates endothelial cell survival. Exp. Cell Res. 294 (2004) 281-289
126. Lee B.S., Fujita M., Khazenzon N.M., Wawrowsky K.A., Wachsmann-Hogiu S., Farkas D.L., Black K.L., Ljubimova J.Y., and Holler E. Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery. Bioconjug. Chem. 17 (2006) 317-326
127. Fujita M., Khazenzon N.M., Ljubimov A.V., Lee B.S., Virtanen I., Holler E., Black K.L., and Ljubimova J.Y. Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis 9 (2006) 183-191
128. Ljubimova J.Y., Fujita M., Khazenzon N.M., Lee B.S., Wachsmann-Hogiu S., Farkas D.L., Black K.L., and Holler E. Nanoconjugate based on polymalic acid for tumor targeting. Chem. Biol. Interact. 171 (2008) 195-203
129. Pal K., Banthia A.K., and Majumdar D.K. Biomedical evaluation of polyvinyl alcohol-gelatin esterified hydrogel for wound dressing. J. Mater. Sci., Mater. Med. 18 (2007) 1889-1894
130. Laurent A., Wassef M., Saint Maurice J.P., Namur J., Pelage J.P., Seron A., Chapot R., and Merland J.J. Arterial distribution of calibrated tris-acryl gelatin and polyvinyl alcohol microspheres in a sheep kidney model. Invest. Radiol. 41 (2006) 8-14
131. Unger F., Wittmar M., Morell F., and Kissel T. Branched polyesters based on poly[vinyl-3-(dialkylamino) alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graft-poly(D, L-lactide-co-glycolide): effects of polymer structure on in vitro degradation behaviour. Biomaterials 29 (2008) 2007-2014
132. Yasukawa T., Kimura H., Tabata Y., Miyamoto H., Honda Y., Ikada Y., and Ogura Y. Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2690-2696
133. Veronese F.M., and Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco 54 (1999) 497-516
134. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., and Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252 (1977) 3582-3586
135. Abuchowski A., van Es T., Palczuk N.C., and Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252 (1977) 3578-3581
136. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
137. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., Berthold W., and Graves M. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 12 (2001) 195-202
138. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., and King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17 (1999) 780-783
139. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev. 54 (2002) 487-504
140. Berna M., Dalzoppo D., Pasut G., Manunta M., Izzo L., Jones A.T., Duncan R., and Veronese F.M. Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake. Biomacromolecules 7 (2006) 146-153
141. Veronese F.M. Peptide, and protein PEGylation: a review of problems and solutions. Biomaterials 22 (2001) 405-417
142. Choe Y.H., Conover C.D., Wu D., Royzen M., Gervacio Y., Borowski V., Mehlig M., and Greenwald R.B. Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J. Control. Release 79 (2002) 55-70
143. Pasut G., Sergi M., and Veronese F.M. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv. Drug Deliv. Rev. 60 (2008) 69-78
144. Subr V., Duncan R., and Kopecek J. Release of macromolecules and daunomycin from hydrophilic gels containing enzymatically degradable bonds. J. Biomater. Sci. Polym. Ed. 1 (1990) 261-278
145. Kratz F., Beyer U., and Schutte M.T. Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carr. Syst. 16 (1999) 245-288
146. Benny O., Fainaru O., Adini A., Cassiola F., Bazinet L., Adini I., Pravda E., Nahmias Y., Koirala S., Corfas G., D'Amato R.J., and Folkman J. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat. Biotechnol. 26 (2008) 799-807
147. Kataoka K., Harada A., and Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47 (2001) 113-131
148. Sakakibara T., Chen F.A., Kida H., Kunieda K., Cuenca R.E., Martin F.J., and Bankert R.B. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res. 56 (1996) 3743-3746
149. Lasic D.D. Doxorubicin in sterically stabilized liposomes. Nature 380 (1996) 561-562
150. Muggia F.M. Doxorubicin-polymer, conjugates: further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res. 5 (1999) 7-8
151. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., and Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release 100 (2004) 41-52
152. Maeda N., Takeuchi Y., Takada M., Namba Y., and Oku N. Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate. Bioorg. Med. Chem. Lett. 14 (2004) 1015-1017
153. Shimizu K., Asai T., Fuse C., Sadzuka Y., Sonobe T., Ogino K., Taki T., Tanaka T., and Oku N. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. Int. J. Pharm. 296 (2005) 133-141
154. Katanasaka Y., Ida T., Asai T., Maeda N., and Oku N. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. Int. J. Pharm. 360 (2008) 219-224
155. Asai T., Shimizu K., Kondo M., Kuromi K., Watanabe K., Ogino K., Taki T., Shuto S., Matsuda A., and Oku N. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett. 520 (2002) 167-170
156. Asai T., Miyazawa S., Maeda N., Hatanaka K., Katanasaka Y., Shimizu K., Shuto S., and Oku N. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. Cancer Sci. 99 (2008) 1029-1033
157. Kim W.J., Yockman J.W., Lee M., Jeong J.H., Kim Y.H., and Kim S.W. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J. Control. Release 106 (2005) 224-234
158. Kim W.J., Yockman J.W., Jeong J.H., Christensen L.V., Lee M., Kim Y.H., and Kim S.W. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J. Control. Release 114 (2006) 381-388
159. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., and Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 296 (2002) 2404-2407
160. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., and Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 (2004) e149
161. Schwendeman S.P. Recent, advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit. Rev. Ther. Drug Carr. Syst. 19 (2002) 73-98
162. Mohamed F., and van der Walle C.F. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J. Pharm. Sci. 97 (2008) 71-87
163. Houchin M.L., and Topp E.M. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. J. Pharm. Sci. 97 (2008) 2395-2404
164. Vasir J.K., and Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59 (2007) 718-728
165. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., and Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J. Control. Release 125 (2008) 193-209
166. Murata N., Takashima Y., Toyoshima K., Yamamoto M., and Okada H. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release 126 (2008) 246-254
167. Benny O., Kim S.K., Gvili K., Radzishevsky I.S., Mor A., Verduzco L., Menon L.G., Black P.M., Machluf M., and Carroll R.S. In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model. FASEB J. 22 (2008) 488-499
168. Becker C.M., Wright R.D., Satchi-Fainaro R., Funakoshi T., Folkman J., Kung A.L., and D'Amato R.J. A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am. J. Pathol. 168 (2006) 2074-2084
169. Eldar A., Vicent M., Miller K., and Satchi-Fainaro R. Targeting αvβ3 Integrin on tumor vasculature using a novel polyglutamic acid-paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2]. Proc. of the AACR meeting: Translational Cancer Medicine: Bridging the Lab and the Clinic in Cancer Medicine conference, Jerusalem, Israel., November 3-6 (2008)